multiple
abstracts
highlighting
assembly
biosciences
hepatitis
b
core
inhibitor
development
programs
accepted
presentation
aasld
liver
meeting
digital
four
posters
including
two
late
breaking
include
new
clinical
preclinical
data
assembly
bio
hepatitis
b
virus
hbv
core
inhibitor
portfolio
south
san
francisco
globe
newswire
assembly
biosciences
nasdaq
asmb
biotechnology
company
developing
innovative
therapeutics
targeting
hepatitis
b
virus
hbv
diseases
associated
microbiome
announced
data
hbv
core
inhibitor
research
development
programs
well
collaborative
translational
study
using
assembly
bio
sensitive
hbv
nucleic
acid
assays
featured
four
abstracts
accepted
presentation
liver
meeting
digital
tlmdx
annual
meeting
american
association
study
liver
diseases
aasld
hosted
virtually
november
tlmdx
poster
presentations
posters
expected
made
available
conference
registrants
online
aalsd
portal
start
meeting
morning
friday
november
available
subsequently
events
presentations
page
investors
section
assembly
website
poster
analysis
safety
profile
hepatitis
b
virus
core
inhibitor
vebicorvir
extension
study
presenter
ira
jacobson
md
director
hepatology
nyu
langone
health
poster
persistently
detectable
serum
hbv
pgrna
associated
subsequent
hcc
development
chronic
hepatitis
b
patients
receiving
chronic
nrti
treatment
presenter
mak
mbbs
mrcp
pdipid
fhkcp
fhkam
department
medicine
queen
mary
hospital
university
hong
kong
hong
kong
late
breaking
poster
changes
viral
antigens
strongly
associated
hbv
pgrna
hbv
dna
studies
vebicorvir
nrti
patients
chronic
hbv
infection
presenter
mark
sulkowski
md
medical
director
viral
hepatitis
center
johns
hopkins
university
school
medicine
late
breaking
poster
amino
acid
substitutions
inhibitor
binding
pocket
hbv
core
protein
confer
differential
changes
susceptibility
three
generations
hbv
core
inhibitors
presenter
dawei
cai
phd
senior
scientist
assembly
biosciences
assembly
biosciences
hbv
core
inhibitor
portfolio
assembly
bio
hbv
portfolio
includes
three
small
molecule
candidates
hbv
core
inhibitors
target
multiple
steps
hbv
replication
cycle
phase
clinical
trials
core
inhibitor
vebicorvir
vbr
administered
nucleos
ide
analogue
reverse
transcriptase
inhibitor
nrti
therapy
shown
statistically
superior
antiviral
activity
hbv
dna
suppression
compared
nrti
therapy
alone
demonstrated
significant
declines
hbv
pgrna
may
indicate
decreased
cccdna
levels
ongoing
phase
extension
trial
assembly
bio
begun
transitioning
patients
therapy
monitor
sustained
virologic
response
svr
assembly
bio
hbv
portfolio
also
includes
two
potent
candidates
phase
development
phase
development
vebicorvir
granted
fast
track
designation
food
drug
administration
treatment
chronic
hbv
infection
hbv
chronic
hepatitis
b
virus
hbv
infection
debilitating
disease
liver
afflicts
million
people
worldwide
million
people
china
estimated
world
health
organization
hbv
global
epidemic
affects
people
hepatitis
c
virus
hcv
hiv
infection
higher
morbidity
mortality
rate
hbv
leading
cause
chronic
liver
disease
need
liver
transplantation
one
million
people
worldwide
die
every
year
causes
current
standard
care
patients
chronic
hbv
infection
suppressive
treatment
medications
reduce
eliminate
viral
replication
resulting
low
cure
rates
significant
unmet
need
new
therapies
treat
hbv
assembly
biosciences
assembly
biosciences
biotechnology
company
developing
innovative
therapeutics
targeting
hepatitis
b
virus
hbv
diseases
associated
microbiome
hbv
program
focused
advancing
new
class
potent
oral
core
inhibitors
potential
increase
cure
rates
chronically
infected
patients
microbiome
program
developing
novel
oral
live
microbial
biotherapeutic
candidates
assembly
bio
fully
integrated
platform
including
robust
process
strain
identification
selection
gmp
manufacturing
expertise
targeted
delivery
lower
gastrointestinal
tract
technology
information
visit
statements
information
press
release
contains
statements
subject
certain
risks
uncertainties
could
cause
actual
results
materially
differ
risks
uncertainties
include
assembly
bio
ability
initiate
complete
clinical
trials
involving
hbv
therapeutic
product
candidates
currently
anticipated
timeframes
safety
efficacy
data
clinical
studies
may
warrant
development
assembly
bio
product
candidates
clinical
nonclinical
data
presented
conferences
may
differentiate
assembly
bio
product
candidates
companies
candidates
assembly
bio
may
observe
sustained
virologic
response
patients
stop
therapy
study
assembly
bio
ability
maintain
financial
resources
necessary
continue
clinical
trials
fund
business
operations
impact
spread
coronavirus
resulting
pandemic
may
assembly
bio
business
operations
including
initiation
continuation
clinical
trials
timing
discussions
regulatory
authorities
risks
identified
time
time
assembly
bio
reports
filed
securities
exchange
commission
sec
urged
consider
statements
include
words
may
would
could
might
believes
hopes
estimates
projects
potential
expects
plans
anticipates
intends
continues
forecast
designed
goal
negative
words
comparable
words
uncertain
assembly
bio
intends
statements
covered
safe
harbor
provisions
contained
section
securities
act
amended
section
securities
exchange
act
amended
information
assembly
bio
risks
uncertainties
fully
detailed
heading
risk
factors
assembly
bio
filings
sec
including
recent
annual
report
form
quarterly
reports
form
current
reports
form
except
required
law
assembly
bio
assumes
obligation
update
publicly
statements
whether
result
new
information
future
events
otherwise
contacts
assembly
biosciences
lauren
glaser
senior
vice
president
investor
relations
corporate
affairs
lglaser
media
contact
sam
brown
audra
friis
asmbmedia
